Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study
Sign Up to like & getrecommendations! Published in 2017 at "Advances in Therapy"
DOI: 10.1007/s12325-016-0472-9
Abstract: AbstractIntroductionCAM2038 q1w (once weekly) and q4w (once monthly) are investigational buprenorphine subcutaneous (SC) formulations based on FluidCrystal® injection depot technology. These two drug products are being developed for opioid dependence treatment, with a target for… read more here.
Keywords: treatment; cam2038 q1w; sublingual buprenorphine; cam2038 ... See more keywords